- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Anthony Rothschild, MD, Discusses How Healthcare Barriers Can Keep Patients From Antipsychotics
Anthony J. Rothschild, MD, says that barriers to expensive antipsychotic drugs are shortsighted. He adds that the American Psychiatric Association, in accordance with some in Congress, recently rejected a CMS decision that would have restricted the number of antidepressants and antipsychotics Medicare beneficiaries could receive.
Anthony J. Rothschild, MD, says that barriers to expensive antipsychotic drugs are shortsighted. He adds that the American Psychiatric Association, in accordance with some in Congress, recently rejected a CMS decision that would have restricted the number of antidepressants and antipsychotics Medicare beneficiaries could receive.
Dr Rothschild is professor and Irving S. and Betty Brudnick Endowed Chair of Psychiatry, University of Massachusetts Medical School; director, UMass Medical Depression Center and Center for Psychopharmacologic Research and Treatment, and program director, Mood Disorders Comprehensive Consultation Clinic at UMass Memorial Medical Center.
“The bottom line is—whether it’s the state’s Medicaid or the federal government on Medicare—is that the amount of money you save on the price of the pill is small compared to the amount of money you might save by giving effective medications, because people are using less healthcare services, both mental and physical,” says Dr Rothschild.
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
